This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Weight Gain and Antipsychotics

Paul Mackin, MD, PhD, MRCPsych

Published: July 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: The recent (November 2004) Commentary by Kaneet al.1 provides readers with a comprehensive overview of thecurrent situation with regard to the controversy surroundingthe association of adverse metabolic effects with atypical antipsychoticdrugs. The discussion reported in the Commentarywas a response to a recently published consensus statement,2as well as the U.S. Food and Drug Administration’s suggestedchanges to labeling, and was intended to advise clinicians howthese recommendations may affect their clinical practice.The panel of experts correctly identify the important areasof uncertainty related to this topic, and they highlight the needfor further rigorous studies designed to examine the differentialeffects of individual atypical agents.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Quick Links: Metabolic Disorder , Side Effects-Medication

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...